Kaleida Health

Buffalo, NY, United States

Kaleida Health

Buffalo, NY, United States
Time filter
Source Type

THOROFARE, NJ--(Marketwired - Dec 19, 2016) - Akers Biosciences, Inc. ( : AKER) ( : AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, has signed a three-year agreement with the Greater New York Hospital Association (GNYHA) to introduce the Company's flagship rapid tests for heparin-induced thrombocytopenia ("HIT") across GNYHA's network of over 300 member hospitals. Founded in 1904, GNYHA is a trade and group purchasing association representing a large number of hospitals and healthcare systems in New York, New Jersey, Connecticut, and Rhode Island; including some of the most prestigious healthcare organizations in the United States. Akers Bio's flagship PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4 tests were designed to quickly determine at -- or near -- the point-of-care if a patient being treated with the widely used blood thinner heparin may be developing HIT. This clinical syndrome reverses heparin's intended therapeutic effect and transforms it into a clotting agent. Patients suffering HIT are at risk of developing limb- and life-threatening complications, so the timely test result provided by the Company's Heparin/PF4 devices is paramount to effective and cost-efficient clinical decision making. Akers Bio believes its rapid tests have the capacity to provide dramatic cost savings for hospitals when compared to traditional testing methodologies for detecting HIT. The Company estimates that a typical hospital can save $0.5 - $1 million per annum in testing, pharmacy, and clinical monitoring costs. Under the terms of the agreement, Akers Bio's flagship PIFA Heparin/PF4 Rapid Assay and PIFA PLUSS PF4 tests will be evaluated at two significant GNYHA member hospitals, Kaleida Health -- which is the largest provider in Western New York -- and Kingsbrook Jewish Medical Center - a major teaching hospital in Brooklyn. The outcome of the evaluations will be shared with GNYHA's extensive member network to which Akers Bio will, with GNYHA's support, begin marketing the Company's tests. "Akers Bio is delighted to have signed a three-year agreement with GNYHA, one of the premier group purchasing organizations in the United States healthcare sector. Their membership includes a diverse listing of prominent and large integrated delivery networks (IDNs) and hospitals. Enhanced access to GNYHA's network has the potential to dramatically increase domestic sales of our flagship product. "We look forward to working with GNYHA to introduce PIFA Heparin/PF4 clinical diagnostic products that will improve effectiveness, operational efficiency and profitable outcomes for their members." Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbio.com. Follow us on Twitter @AkersBio. Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Hannan E.L.,Albany State University | Samadashvili Z.,Albany State University | Stamato N.J.,Campbell County Memorial Hospital | Lahey S.J.,University of Connecticut | And 7 more authors.
JACC: Cardiovascular Interventions | Year: 2016

Objectives The purpose of this study was to investigate changes in the use of transcatheter aortic valve replacement (TAVR) relative to surgical aortic valve replacement (SAVR) and to examine relative 1-year TAVR and SAVR outcomes in 2011 to 2012 in a population-based setting. Background TAVR has become a popular option for patients with severe aortic stenosis, particularly for higher-risk patients. Methods New York's Cardiac Surgery Reporting System was used to identify TAVR and SAVR volumes and to propensity match TAVR and SAVR patients using numerous patient risk factors contained in the registry to compare 1-year mortality rates. Mortality rates were also compared for different levels of patient risk. Results The total number of aortic valve replacement patients increased from 2,291 in 2011 to 2,899 in 2012, an increase of 27%. The volume of SAVR patients increased by 7.1% from 1,994 to 2,135 and the volume of TAVR patients increased 157% from 297 to 764. The percentage of SAVR patients that were at higher risk (≥3% New York State [NYS] score, equivalent to a Society of Thoracic Surgeons score of about 8%) decreased from 27% to 23%, and the percentage of TAVR patients that were at higher risk decreased from 83% to 76%. There was no significant difference in 1-year mortality between TAVR and SAVR patients (15.6% vs. 13.1%; hazard ratio [HR]: 1.30 [95% confidence interval (CI): 0.89 to 1.92]). There were no differences among patients with NYS score <3% (12.5% vs. 10.2%; HR: 1.42 [95% CI: 0.68 to 2.97]) or among patients with NYS score ≥3% (17.1% vs. 14.5%; HR: 1.27 [95% CI: 0.81 to 1.98]). Conclusions TAVR has assumed a much larger share of all aortic valve replacements for severe aortic stenosis, and the average level of pre-procedural risk has decreased substantially. There are no differences between 1-year mortality rates for TAVR and SAVR patients. © 2016 by the American College of Cardiology Foundation.

News Article | February 15, 2017
Site: www.prweb.com

With “ELIXR™" Tour Ball Launch Slated for March, Former First Niagara CEO Named President of Revolutionary Brand BUFFALO, NY – OnCore Golf announced today that prominent Buffalo-based business leader John R. Koelmel has been named company President. Koelmel is an active early-stage investor, current Chair of the New York Power Authority (NYPA), and former CEO of First Niagara Financial Group. With years of financial, sports industry and business experience, as well deep community and regional ties, Koelmel will help the disruptive and innovative ball company execute its aggressive growth plans, including the impending launch of its first ever high performance tour ball—the ELIXR™. “It is my pleasure to welcome John Koelmel to the OnCore Golf team,” said Keith Blakely, OnCore Golf Chairman and Chief Executive Officer. “With an incredible career spanning leadership of a major financial institution, oversight of one of North America’s most innovative sports facilities, fueling and advising Buffalo Niagara’s startup eco-system, all while helping to power New York State—John’s resume and the passion he holds for our company speaks for itself. I feel strongly that his joining the Company as President will undoubtedly help drive OnCore Golf to the next level.” Koelmel joins OnCore Golf following a series of important company achievements in 2016, continuing to implement the vision of co-founders Steve Coulton and Bret Blakely, including: finalizing the Company’s first-ever tour ball—the ELIXR™—to complement the revolutionary hollow metal core CALIBER and low compression AVANT balls, developing new and differentiated brand positioning, expanding OnCore’s international distribution agreements in Asia, South America, and Europe, and the addition of former Nike Golf representative Brian McGahey as Director of Business and Player Development. “OnCore Golf is poised for serious growth, and I’m excited to have the opportunity to help the Company reach its fullest potential,” said Koelmel. “Our groundbreaking innovation literally made history when the USGA rewrote its rules on allowable golf ball construction for just the second time in 100 years, permitting the hollow metal core to be considered a conforming technology—and our best is yet to come. Having a full suite of high-performing and more affordable ball products positions us very well—and exactly at the right time—to energize the game for both the current and next generation of golfers.” To further its dynamic brand messaging and Blue Ocean approach to the industry, the company has established marketing partnerships with Buffalo and Rochester, NY-based integrated communications agency The Martin Group, high-end production firm dPost, lead generation shop Scale Solutions, NYC and Buffalo-based KC Public Relations, and Wash., DC-based golf specialists the Buffalo Agency. As OnCore Golf prepares for its public release of the ELIXR™—which has been tested with tremendous reviews and was recently previewed at the PGA Merchandise Show in Orlando, FL—the company has confirmed an official production timetable, with initial customer and retail distribution set for March 2017. “As an investor and Board member for the last eighteen months, I’ve seen the company systematically upgrade talent, establish critical strategic partnerships and distribution paths, focus its plan, sharpen approaches, and significantly enhance the overall mix of golf balls that we have to offer,” continued Koelmel. “That is why all of us on the OnCore Golf team are confident 2017 will be our most successful year since company inception, setting the foundation for very meaningful growth in the years that follow.” The OnCore Board of Directors also includes Allen F. (“Pete”) Grum, President and CEO of Rand Capital Corporation (NASDAQ:RAND), an early investor, Joseph White, former President of Gary Player Sports, and Ron Schreiber, representing Z80 Labs, the Buffalo-based technology incubator. Koelmel comes to OnCore while having individually invested in several startup and early-stage businesses over the last two years. This engagement also follows his role as President of HARBORCENTER, where he oversaw the formation of Terry and Kim Pegula’s $200 million hockey and entertainment complex on the City of Buffalo’s waterfront. Previously, Koelmel served as President and CEO of First Niagara Financial Group, where he led the organization’s growth to a top-30 U.S. bank. He started his career in 1974 with KPMG LLP, concluding his 26-year tenure as Managing Partner of the firm’s Upstate New York operations. “Caring about community, growing our region, and investing time, talent and real dollars with young entrepreneurs and startup businesses has always been a strong passion of mine,” remarked Koelmel. “It’s one of the reasons why I decided to invest in and ultimately join OnCore Golf, and it’s certainly why I regularly encourage colleagues, friends and community members to get involved in our region’s early-stage startup ecosystem.” More About John R. Koelmel Koelmel continues to lead JRK Advisors LLC, where he has invested in several early-stage companies in a wide range of industries, including energy, manufacturing and fintech. He also remains heavily involved in 43North, the $5 million business plan competition made possible by Governor Andrew Cuomo’s original Buffalo Billion initiative. Koelmel also serves as Board Chair of the Buffalo Center for Arts & Technology in addition to his role with NYPA. A Western New York native, Koelmel is a resident of East Amherst, N.Y., where he lives with his wife, Marsha. For many years Koelmel has been heavily involved with community and charitable organizations across the Buffalo Niagara region, including the Kaleida Health and Great Lakes Health boards. He is a former Buffalo News “Citizen of the Year,” Buffalo Renaissance Foundation “Man of the Year,” Leadership Niagara “Leader of the Year,” and an American Banker “Community Banker of the Year” award recipient. More About OnCore Golf OnCore Golf is a brand dedicated to delivering breakthrough technology and innovation, while inspiring golfers at all skill levels and abilities. Founded by two young entrepreneurs—Bret Blakely and Steve Coulton—and fueled by a team of world-class inventors, OnCore Golf disrupted the golf ball industry through development of the first-ever USGA Conforming Hollow Core Ball, while unleashing a growing suite of products across North America and beyond. The company’s offerings include the extremely accurate CALIBER ball, the five star-rated AVANT with SoftCell technology to increase feel, durability and distance, as well as the dynamic ELIXR™ Tour ball. Why OnCore Golf? Because it’s time to add M.O.R.E. (maximum performance, optimal trajectory, revolutionary technology and explosive velocity) to your game. For additional information, visit http://www.OnCoreGolf.com.

News Article | January 21, 2016
Site: www.labdesignnews.com

Projections released by the U.S. Department of Education paint a bright future for jobs in the science, technology, engineering and mathematics (STEM) fields. As populations grow, natural resources diminish, disease prevention and treatment become more complex and evolutionary and universal mysteries continue to be explored, science and technology will remain critical to expanding human knowledge and solving challenges of today and for the future. Opportunities abound for STEM graduates today, but preparing enough STEM graduates to drive the scientific breakthroughs and technological innovations of tomorrow will be a daunting task for colleges and universities across the country. The U.S. President’s Council of Advisors on Science and Technology predicts that in the next decade, we will need approximately 1 million more STEM professionals than we will produce at our current rate. Currently, about 300,000 graduates obtain Bachelor and Associate degrees in STEM fields every year. In order to create this new workforce of 1 million additional STEM experts, that number needs to increase by 100,000 annually. The challenge is clear: Universities must attract more students to STEM programs. However, once these students have enrolled, another challenge begins to unfold: Only about 40 percent of students who enroll in STEM programs graduate with STEM degrees. The remaining 60 percent switch to non-STEM fields or drop out of college entirely. To address the challenges of attraction and retention, educational institutions throughout the country are trading in traditional teaching methods for new pedagogical techniques. These new methods move beyond a model where students passively listen to lectures and cram for tests, to methods that engage students in activities, enable collaboration across STEM disciplines and encourage students to use their hands just as much as their heads. With these new approaches to learning and teaching come new approaches to designing learning environments. These new spaces are eliminating the stereotypes associated with traditional STEM classrooms and fostering the type of creative brilliance that can help us educate and prepare one million new STEM graduates. Here are three ideas every university should consider when rethinking their STEM learning spaces to better recruit and retain students for the future. Get out of the basement Traditionally, STEM teaching labs and research spaces were located in building cores or basements. These underground “lairs” were uncomfortable and uninviting to students and faculty using these facilities. They featured little to no windows, no natural light and the overall environment felt more institutional than educational. For students that didn’t have a class assigned to these spaces, the labs were relatively unknown, and were considered untouchable and intimidating. Countless studies show the design of classroom environments influence students’ motivation and learning, and universities are seeing the value in encouraging the student body to observe the scientific process to raise curiosity and interest. From a design perspective, we use the term “putting science on display” pretty regularly. The general idea is to place science classrooms and labs in public, high-traffic areas. Instead of solid walls, expansive floor-to-ceiling windows celebrate the sciences and allow passersby the opportunity to observe research and watch it unfold. This helps make science an approachable, open process, and as an added benefit, it gives universities the chance to show off their cool research equipment. The University of Buffalo has embraced this idea with its Clinical Translational Research Center (CTRC). Embedded in the same building as Kaleida Health’s Gates Vascular Institute, the CTRC uses interior glass throughout the building to show science in an open, transparent process. Embrace startup culture A key component of successful STEM programs is experimentation. For example, if you look at the most successful technology startups over the last 10 years, very few started in a formal academic settings. More often than not, they started in garages or coffee shops—places with more sofas than fixed bench space. There’s a lot STEM learning environments can learn from these spaces, specifically in how they encourage free thinking and experimentation. Taking inspiration from startups, our team at CannonDesign is seeing an increase in makerspace, hackerspace and innovation hubs within STEM buildings. These spaces serve a pretty basic purpose: nurturing creativity, encouraging experimentation and stimulating intellectual inquiry in an informal setting. They don’t act exclusively as labs, garages or workshops, but they do include many of the tools found in these space (3-D printers, welding machines, computers, building materials). The Univ. of Utah sees the value in such spaces with their new Lassonde Studios Entrepreneurial building that features a 20,000-sf making/planning/hacking space to foster interdisciplinary and cross-disciplinary “mash-ups” extending beyond STEM disciplines and including others, such as business majors. Infuse appropriate technology into S&T academic environments Millennials and Generation Z grew up in a digital world and expect to take full advantage of technology in every aspect of life, especially college. However, technology hasn’t revolutionized education the way it has other industries. STEM learning environments can be leading examples for how using technology can enhance learning by making it more engaging and accessible. The flipped classroom is a good example of an effective use of technology for enhanced learning. The flipped classroom is a pedagogical model that has students watch video lectures and complete homework prior to class. Doing this creates richer face-to-face interactions when students are actually in class; instead of listening to a lecture, they spend their time asking questions, participating in hands-on activities and even getting involved in real university research efforts. On the most dramatic end of the spectrum, some universities are using virtual reality, simulation and gaming to inspire and educate future STEM innovators. These tools allow students to quite literally take part in technology. For example, CAVE environments, which are rooms wrapped in screens that project 3D virtual environments, allow students to immerse themselves in a setting and actually interact with what they’re seeing. From an infrastructure design standpoint, these technology-rich spaces require a building that provides enhanced server space, room for complex computing platforms, and the power and cooling sources to keep everything up and running. One interesting trend our team is also seeing related to technology is a decrease in dedicated computer labs. Prior to the days of constant connectivity, computer labs acted as the hub of higher education buildings. But today, 90 percent of students own a laptop, 86 percent of students own a smartphone and 47 percent of students own a tablet. The need to access university-owned equipment is dwindling, and the need to plug in personal devices and work anywhere is the new norm. There’s no denying universities need to prove themselves up to the challenge of attracting and retaining the much needed next generation of STEM professionals. How they choose to design their STEM learning environments can play a big role in helping them meet this challenge and exceed current projections. Stephen Blair leads CannonDesign’s global science and technology practice, focused on helping academic and corporate institutions design solutions that turn challenges into opportunities for success. www.cannondesign.com

O'Brien-Irr M.S.,State University of New York at Buffalo | Dosluoglu H.H.,State University of New York at Buffalo | Harris L.M.,State University of New York at Buffalo | Harris L.M.,Kaleida Health | And 2 more authors.
Journal of Vascular Surgery | Year: 2011

Objective: This study evaluated outcomes after endovascular intervention (EVI) for chronic critical limb ischemia (CLI) by Rutherford category (RC) 4, rest pain; and 5, tissue loss. Methods: The medical records of all EVI performed for RC-4 to RC-5 by vascular surgeons at a single institution during a 3-year period were reviewed for sustained clinical success (SCS), defined as Rutherford improvement score (RIS) 2+, without target extremity revascularization (TER). The RC-5 group was evaluated for patency until healing and healing ≤4 months without recurrence or new ulceration. Secondary sustained clinical success (SSCS) was a RIS of 2+ with TER. The RC-5 group was evaluated for patency until healing and healing at any time during follow-up, without recurrent or new ulceration. Significance was established at the 0.05 level. Results: Of 106 EVI performed for CLI, 78 (74%) were RC-5. There were 39 (37%) men. Mean age was 73 ± 12 years. Mean follow-up was 19 months (range, 1-44 months). RC-5 patients were significantly more likely than RC-4 to be diabetic (58% vs 32%; P = .020), dialysis dependent (14% vs 0%; P = .036), and to require distal EVI (53% vs 29%; P = .029). RC-4 patients were more likely to be current smokers (57% vs 32%; P = .023). At 24 months, survival was comparable, with RC-4 at 84% ± 8% vs RC-5 at 62% ± 7% (P = .09), but limb salvage was significantly better for RC-4 (100%) vs RC-5 (83% ± 4%; P = .026), as was SCS (48% vs 21%; P = .006) and SSCS (85% vs 39%; P < .001). Independent predictors of failed SSCS were diabetes (odds ratio [OR], 2.83; 95% confidence interval [CI], 1.07-7.46; P = .036), congestive heart failure (CHF; OR, 3.62; 95% CI, 1.19-10.99; P = .023), and RC-5 (OR, 5.5; 95% CI, 2.4-30.3; P = .001). SSCS was 94% in RC-4 patients without diabetes mellitus (DM) or CHF and 10% in RC-5 with DM or CHF (P < .001) but improved to 67% in RC-5 when neither CHF nor DM were present (P = .004). Conclusions: RC-4 have fewer comorbidities, less advanced ischemia, and better outcome than RC-5. These groups should be evaluated individually. Limb salvage was acceptable, yet early wound healing without TER (SCS) occurred in only 21%. RC-5, DM, and CHF were predictors of poor SSCS. Careful selection of patients should improve outcome. © 2011 Society for Vascular Surgery.

O'Brien-Irr M.S.,State University of New York at Buffalo | Harris L.M.,State University of New York at Buffalo | Harris L.M.,Kaleida Health | Dosluoglu H.H.,State University of New York at Buffalo | And 2 more authors.
Journal of the American College of Surgeons | Year: 2012

Type or lack of insurance may affect access to care, treatment, and outcomes. We evaluated trends for surgical management of all peripheral arterial disease (PAD) in-hospital admissions by insurer status in New York State. Statewide Planning and Research Cooperative System (SPARCS) data were obtained and cross-referenced for diagnostic and procedure codes. Data from 2001 to 2002 were averaged and used as a baseline. Change in indication, volume of admissions, procedures, and amputations were calculated for the years 2003 to 2008 and were analyzed by insurer status. There were 83,949 admissions. Endovascular intervention (EVI) increased tremendously for all indications and was used equally in the insured and uninsured. Among critical limb ischemia admissions, patients with private insurance were significantly more likely to be admitted for rest pain and significantly less likely to be admitted for gangrene (p < 0.001). Admission for gangrene declined for all. As EVI increased, amputation decreased and was significantly lowest in patients with private insurance (p < 0.001). Amputation was significantly higher in Medicaid than other insured (Medicaid vs private, p < 0.001; Medicaid vs Medicare, p = 0.003), but comparable to the uninsured (p = 0.08). Age greater than 65 years and low socioeconomic class or minority status were significant risks for gangrene (p = 0.014; p < 0.001) and ultimate amputation (p = 0.05; p < 0.001). Lack of insurance may pose a similar risk. EVI increased tremendously and was used without disparity across insurer status. Amputation declined steadily and may have been related to increased EVI or to decreased admission for gangrene. Advanced age, low socioeconomic class or minority status, and lack of insurance negatively affect presentation and limb salvage. Universal health care may be beneficial in improving outcomes but must address root causes for delayed presentation. © 2012 American College of Surgeons.

Hsiao C.-B.,State University of New York at Buffalo | Hsiao C.-B.,Kaleida Health | Dryja D.,Kaleida Health | Abbatessa L.,State University of New York at Buffalo | Patel P.H.,Kaleida Health
Journal of Clinical Microbiology | Year: 2010

Staphylococcus aureus is the most common etiologic agent of skin abscesses. The regional rate of methicillinresistant S. aureus (MRSA) abscesses may reflect the prevalence of local community-acquired MRSA (CAMRSA). A retrospective study was conducted to compare the antimicrobial susceptibility patterns of S. aureus isolates recovered from abscesses from 2003 to 2006 from patients at hospitals of the Kaleida Health System in western New York. S. aureus susceptibility information was obtained from a Vitek Legacy system, and the location and source of each isolate were identified. EpiInfo software was used to analyze the antimicrobial susceptibilities of all isolates and the trends in the rates of MRSA. A total of 2,848 S. aureus abscesses were identified by the Kaleida Health Clinical Microbiology Laboratory. Of those, 978 S. aureus abscess events occurred in four hospitals, including three adult facilities (547 episodes with 62 cases of bacteremia) and one children's facility (431 episodes with 2 cases of bacteremia). The MRSA rates in adults increased from 56% (2003) to 71% (2006), and that in children increased from 26% (2003) to 64% (2006). Of the MRSA isolates in the children's samples, more than 92% were susceptible to clindamycin. Of the MRSA isolates in the adult samples, 50% were susceptible to clindamycin in 2003 and 2004, whereas greater than 75% were susceptible in 2005 and 2006. The increased rates of MRSA abscesses with susceptibility to clindamycin may reflect the high prevalence level of CAMRSA in the western New York community. The variations in S. aureus susceptibilities could serve as an indicator of the changing resistance patterns within a broad urban community. Copyright © 2010, American Society for Microbiology. All Rights Reserved.

Ghanim H.,State University of New York at Buffalo | Sia C.L.,Kaleida Health | Upadhyay M.,Kaleida Health | Korzeniewski K.,Kaleida Health | And 5 more authors.
American Journal of Clinical Nutrition | Year: 2010

Background: The intake of glucose or a high-fat, high-carbohydrate (HFHC) meal, but not orange juice, induces an increase in inflammation and oxidative stress in circulating mononuclear cells (MNCs) of normal-weight subjects. Objective: We investigated the effect of orange juice on HFHC meal-induced inflammation and oxidative stress and the expression of plasma endotoxin and Toll-like receptors (TLRs). Design: Three groups (10 subjects in each group) of normal, healthy subjects were asked to drink water or 300 kcal glucose or orange juice in combination with a 900-kcal HFHC meal. Blood samples were obtained before and 1, 3, and 5 h after the drinks and meal combinations were consumed. Results: Protein expression of the NADPH oxidase subunit p47phox, phosphorylated and total p38 mitogen-activated protein kinase, and suppressor of cytokine signaling-3; TLR2 and TLR4 messenger RNA (mRNA) and protein expression; mRNA expression of matrix metalloproteinase (MMP)-9 in MNCs; and plasma concentrations of endotoxin and MMP-9 increased significantly after glucose or water were consumed with the meal but not when orange juice was consumed with the meal. The generation of reactive oxygen species by polymorphonuclear cells was significantly lower when orange juice was added to the meal than when water or glucose was added to the meal. Conclusions: The combination of glucose or water and the HFHC meal induced oxidative and inflammatory stress and an increase in TLR expression and plasma endotoxin concentrations. In contrast, orange juice intake with the HFHC meal prevented meal-induced oxidative and inflammatory stress, including the increase in endotoxin and TLR expression. These observations may help explain the mechanisms underlying postprandial oxidative stress and inflammation, pathogenesis of insulin resistance, and atherosclerosis. © 2010 American Society for Nutrition.

Dhindsa S.,State University of New York at Buffalo | Dhindsa S.,Kaleida Health | Furlanetto R.,Quest Diagnostics Nichols Institute | Vora M.,State University of New York at Buffalo | And 7 more authors.
Diabetes Care | Year: 2011

OBJECTIVE - It has been suggested that the high prevalence of subnormal free testosterone concentrations, along with low or in appropriately normal gonadotropins in men with type 2 diabetes, may be the result of an increase in plasma estradiol concentrations secondary to an increase in aromatase activity in the adipose tissue that leads to the suppression of the hypothalamohypophyseal-gonadal axis. RESEARCH DESIGN AND METHODS - To investigate this hypothesis, plasma estradiol, testosterone, leutinizing hormone, follicle-stimulating hormone, and sex hormone-binding globulin (SHBG) concentrations were measured in fasting blood samples of 240 men with type 2 diabetes. Free estradiol concentrations were either calculated (n = 198) using total estradiol and SHBG measured by immunoassay or directly measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) and equilibrium dialysis (n = 102). RESULTS - The calculated free estradiol concentration in men with subnormal free testosterone concentrations was lower than that in men with normal free testosterone concentrations (median 0.047 vs. 0.063 ng/dL, P < 0.001). Directly measured (LC-MS/MS) free estradiol concentrations were also lower in men with subnormal free testosterone concentrations (median 0.025 vs. 0.045 ng/dL, P = 0.008). Free estradiol concentrations were directly related to free testosterone but not to BMI or age. CONCLUSIONS - These data show that the suppression of the hypothalamo-hypophysealgonadal axis in patients with subnormal free testosterone concentrations and type 2 diabetes is not associated with increased estradiol concentrations. The pathogenesis of subnormal free testosterone concentrations in type 2 diabetes needs to be investigated further. © 2011 by the American Diabetes Association.

Siddiqui A.H.,University at Buffalo Neurosurgery | Siddiqui A.H.,Toshiba Corporation | Siddiqui A.H.,Kaleida Health | Kan P.,University at Buffalo Neurosurgery | And 9 more authors.
Neurosurgery | Year: 2012

BACKGROUND AND IMPORTANCE: The Pipeline Embolization Device (PED) is a flow diverter designed to treat intracranial aneurysms through endoluminal parent vessel reconstruction. The role of adjunctive coil embolization is unknown. CLINICAL PRESENTATION: This report details the authors' experience with the PED in 2 patients with symptomatic, giant distal intracranial aneurysms (1 basilar artery and 1 M1 segment middle cerebral artery). Both patients had successful parent vessel reconstruction. In the first patient, the basilar artery aneurysm was treated with PEDs alone, and the patient experienced early fatal brainstem hemorrhage from aneurysm rupture. In the second patient, the M1 aneurysm was treated with 2 PEDs along with dense coil embolization, with a good initial angiographic result. This patient experienced acute thrombosis of the PED post-procedure, likely related to mass effect and thrombogenicity of the dense coil mass. CONCLUSION: Flow diversion is an evolutionary step in the treatment of giant intracranial aneurysms. However, complete aneurysm occlusion occurs over a delayed period. The authors recommend placement of coils in addition to PED in the treatment of large or giant distal intracranial aneurysms in an attempt to protect the dome. However, robust packing is to be avoided because it can lead to acute PED thrombotic or compressive occlusion. Copyright © 2012 by the Congress of Neurological Surgeons.

Loading Kaleida Health collaborators
Loading Kaleida Health collaborators